Clinical efficacy and safety of intravenous esmolol in the treatment of supraventricular tachyarrhythmias: Multiple centers analysis of 309 cases

Kai You,Xiaowei Yan,HaiTao Ren

1996-01-01

Abstract:To evaluate the antiarrhythmic effect and safetyness of esmolol, we observed 309 patients with supraventricular tachyarrhythmia from 8 medical centers, including atria fibrillation or flutter, paroxysomal supraventricular tachycardia, automatic atria tachycardia, sinus tachycardia (noncompensated, required treatment, ventricular heart rate �� 120 bpm) and sinus tachycardia in the perioperative period (heart rate �� 100 bpm). Test esmolol group (Qilu Pharmaceutical Co.) included 225 cases, controlled esmolol group (DU Pont Pharmaceutical Co.), 49 cases, and controlled metoprolol group, 35 cases, according to the kind of arrhythmia, a randomized paracontrolled, single-blind study was performed. In the test esmolol group, 74.6% of the cases achieved good therapeutical response (defined as ventricular heart rate < 100 bpm, or > 20% reduction in the average baseline heart rate, or reversion to normal sinus rhythm). The therapeutic response was similar to that of the two controlled groups. Best therapeutic response exhibited in the patients with sinus tachycardia (87.5%). 1/3 cases of ectopic arrhythmia reversed to normal sinus rhythm. Most of the patients in the test esmolol group tolerated well. The adverse reaction exhibited in 6.2% of patients who received test esmolol being hypotension (4.0%), nausea, sweeting, palpitation, depressing feeling in the chest.